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Cognitive-behavioural therapy has no effect on
disease activity but improves quality of life in
subgroups of patients with inflammatory bowel
disease: a pilot randomised controlled trial
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and Jane M Andrews4,6,8
Abstract
Background: Studies have demonstrated usefulness of cognitive-behavioural therapy (CBT) in managing distress in
inflammatory bowel disease (IBD); however, few have focused on IBD course. The present trial aimed to investigate
whether adding CBT to standard treatment prolongs remission in IBD in comparison to standard therapy alone.
Methods: A 2-arm parallel pragmatic randomised controlled trial (+CBT – standard care plus either face-to-face
(F2F) or online CBT over 10 weeks versus standard care alone (SC)) was conducted with adult patients in remission.
IBD remission at 12 months since baseline was the primary outcome measure while the secondary outcome
measures were mental health status and quality of life (QoL). Linear mixed-effect models were used to compare
groups on outcome variables while controlling for baseline.
Results: Participants were 174 patients with IBD (90 +CBT, 84 SC). There was no difference in remission rates
between groups, with similar numbers flaring at 12 months. Groups did not differ in anxiety, depression or coping
at 6 or 12 months (p >0.05). When only participants classified as ‘in need’ (young, high baseline IBD activity,
recently diagnosed; poor mental health) were examined in the post-hoc analysis (n = 74, 34 CBT and 40 controls),
CBT significantly improved mental QoL (p = .034, d = .56) at 6 months. Online CBT group had a higher score on
Precontemplation than the F2F group, which is consistent with less developed coping with IBD in the cCBT
group (p = .045).
Conclusions: Future studies should direct psychological interventions to patients ‘in need’ and attempt to recruit
larger samples to compensate for significant attrition when using online CBT.
Trial registration: The protocol was registered on 21/10/2009 with the Australian New Zealand Clinical Trials
Registry (ID: ACTRN12609000913279).
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Background
Inflammatory bowel disease (IBD) is a chronic inflamma-
tory condition of the gastrointestinal (GI) tract, with a
rising incidence worldwide. IBD’s aetiology is thought
to involve a deregulated immune response to intestinal
microbiome, triggered by environmental factors, in those
with a genetic susceptibility. In addition, a psycho-neuro-
immunological view of IBD has developed in recent years
due to intriguing observations that psychological status
can directly influence inflammatory lesions in the gut [1].
Although IBD has not, to date, been confirmed to be caus-
ally linked to psychological factors, psychological stress
has been reported to be one of the strongest predictors of
symptomatic disease course [2,3] and also linked to in-
creased inflammation [4]. A review by Graff et al. has
demonstrated that depression negatively influences IBD
course [5]. However, it needs to be acknowledged that in
the majority of the available studies, reported symptoms
rather than actual inflammation (measured e.g. using fecal
calprotectin or histology scores) are the outcome measure
and thus it remains unclear how much of this relationship
is explained by symptom perception versus inflammatory
activity. Further to this, although the research on stress,
depression and inflammation in animals has provided
more than convincing evidence of their inter-relationships
in IBD, replicating these observations in humans is
challenging for ethical reasons. Hence, the question of this
relationship needs to be addressed indirectly by testing
whether delivering a therapy known to enhance psycho-
logical wellbeing (i.e. psychotherapy) may protect against
IBD-related inflammation and prevent flares.
Given the observed relationship between stress, depres-
sion and IBD disease course and also the encouraging data
on the treatment of functional gut disorders with psycho-
therapy [6], interest in the possible efficacy of psycho-
logical interventions in IBD has been growing. In recent
years, several reviews have been published on the efficacy
of psychotherapy for QoL, emotional status and remis-
sion/flare status in IBD [7-10]. A Cochrane meta-analysis
of randomized controlled trials found no evidence for the
efficacy of psychotherapy in improving QoL, emotional
status or proportion of patients not in remission in the
short term or at 12 months in unselected adults with IBD,
although it suggested that psychotherapy may result
in benefits for subgroups of patients [8]. However, here,
ideologically dissimilar psychological interventions were
grouped together possibly clouding the conclusions. One
of the recent reviews [9] has addressed this weakness
of the previous review and concluded that cognitive-
behavioural therapy (CBT) - a psychotherapy where people
are taught to identify and modify unhelpful thinking styles
and maladaptive behaviours - is associated with improve-
ment in distress, although it has resulted in benefits with
respect to IBD symptoms only in some reports.
Thus, the present trial aimed to investigate whether CBT
in addition to standard medical therapy prolongs remission
in IBD in comparison with standard therapy alone. As IBD
is a life-long condition [11] and there is the potential for a
bidirectional interaction between psychological status and
disease relapse [12], and the additional factor that life
stresses and psychological status are not constant over
time, we chose to examine the effect of CBT in a general
cohort of IBD patients in remission rather than only those
with current depression and/or anxiety. Given the primary
outcome measure and the main focus of the trial was on
disease activity over time rather than treating anxiety or de-
pression, this was considered the most optimal approach.
It was hypothesised that the benefits of adding CBT
would be two-fold:
i) increase in the proportion of IBD patients remaining
free of a flare in comparison to standard therapy and
ii) increase in health-related quality of life (QoL).
Methods
Design
The study was a 2-arm parallel randomised controlled trial
(RCT) (standard care plus CBT (+CBT) versus standard
care alone (SC)). The trial design was pragmatic as it of-
fered those in the experimental group a choice of complet-
ing the intervention face-to-face (F2F) or online (cCBT).
The psychological intervention was not compared with
time-matched psychological placebo as CBT has previously
been found to have a significant effect over and above the
placebo in many studies [13]. In this real world study,
SC (involving additional visits to the clinic to give blood
and complete the questionnaires at baseline, 6 and 12
months) was the preferred comparator as this is the current
best practice. The study was registered in the Australian
New Zealand Trial Registry (ACTRN12609000913279).
The reporting of this study followed the CONSORT state-
ment format in relation to pragmatic trials [14]. Partial con-
cealment was used at invitation/enrolment as SC patients
were told that we were examining how psychological health
influenced IBD behaviour and were unaware of the +CBT
arm of the study. Blinding the experimental group was not
possible as is often the case in psychotherapy trials.
Participants
Participants were recruited from two Gastroenterology
Clinics in Australia, together serving approximately 2,000
IBD patients.
Inclusion criteria
Patients had to meet ALL of the following criteria: 1). a
clinically established diagnosis of IBD (according to usual
clinical practice by combination of clinical, radiologic,
endoscopic and histologic grounds in a tertiary care IBD
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centre); 2). current clinical remission or mild symptoms
only for at least 3 months as evidenced by disease activity
index, notes review, blood results and report from their
treating gastroenterologist, if necessary (complete loss of
GI symptoms in IBD is uncommon even during endo-
scopic remission); 3). sufficient English to understand,
answer questionnaires and participate in therapy; 4). 18
years old or older; 5). competence to consent; 6). will-
ingness to complete CBT sessions.
Exclusion criteria
Patients were excluded if they met ANY of the following:
1). serious mental illness (e.g. psychosis, schizophrenia) or
alcohol/substance dependence as diagnosed by the Clin-
ical Psychologist; 2). currently undergoing psychotherapy;
3). significant cognitive impairment. Antidepressants were
not an exclusion as antidepressants are commonly used in
IBD not necessarily to treat anxiety or depression but ra-
ther, in a similar fashion they are used in functional gut
disorders, to manage pain and abdominal discomfort
and thus may be considered usual care [15].
Procedure
IBD databases were screened by the Clinics’ IBD nurses.
Potentially eligible IBD patients were then contacted by a
letter. Further approaches were made to patients who did
not opt-out or answer the letter within 4 weeks, up to
three times. Patients from outside of the hospitals who
were known to the clinics’ doctors were contacted by their
own treating doctors by letters. Eligible patients were then
randomised to either the +CBT or SC group. A simple
randomisation method was used using a table of computer
generated random numbers (in blocks of four) in the pro-
portion of 2:1 (experimental vs. control). This proportion
was used as we predicted problems in recruiting to the ex-
perimental arm (due to a larger participant burden) and
assumed that we needed to approach twice as many ex-
perimental participants to eventually obtain the same
number of participants in both groups. A randomisation
schedule was created by the researcher with no direct pa-
tient contact using computer software (AE). Participants
were enrolled by Research Nurses (not this study’s investi-
gators) who also assigned participants to interventions.
The +CBT arm had two subgroups which for the pur-
pose of the main analysis were treated as one: a F2F CBT
group that met at the hospital; and a cCBT group where
intervention was delivered online. Those who could not
commit to the time/travel involved in F2F CBT were of-
fered therapy online which was designed to exactly mirror
the F2F intervention. F2F group met weekly at the hospital
for two-hour sessions delivered by a psychologist while
cCBT group received sessions of similar length online
(self-directed). Sessions are presented in detail elsewhere
(http://www.tameyourgut.com/); their content was identical
for both experimental sub-groups. Irrespective of CBT al-
location, F2F and cCBT groups both reported for blood
tests and assessments at the same times. See Table 1 for
assessment points. Reminders about the next session
were sent via email or text message weekly for the dur-
ation of the intervention for both CBT subgroups.
Intervention
CBT was a 10-week group program designed specifically
for this patient population by senior clinical psycholo-
gists working at the hospital Clinical Psychology Unit
(not study investigators). This length is consistent with
the maximum annual number of psychotherapy sessions
with a psychologist currently available to Australians as
part of the Medicare Better Access initiative [16]. Based
on previous studies [17,18] we assumed that CBT would
perform consistently irrespective of delivery mode. The
CBT program (2 hours each week) consisted of: 1) Edu-
cation about IBD and CBT; 2) Stress and relaxation; 3)
Automatic thoughts and cognitive distortions; 4) Cogni-
tive restructuring; 5) Exposure and overcoming avoidance;
6) Coping strategies; 7) Assertiveness training; 8) Relation-
ships and communication; 9) Attention and distraction;
and 10) Relapse prevention for mental health problems.
Attendance at each weekly session was noted by the
psychologist and registered by the CBT website in the case
of online groups. Compliance with the program was moni-
tored by the psychologist on a regular basis and strategies
to minimise attrition included regular reminders (tele-
phone, email). Non-compliant patients were contacted by
the psychologist individually and inquired about their
views on how this may be improved. Withdrawing pa-
tients were asked for permission to retain data to date.
Treatment fidelity was maintained by using the same
protocol for both groups within the CBT arm. Online CBT
was provided using the university IT infrastructure support.
Sample size
The power calculation was prepared for the primary out-
come measure being in remission at follow-up for the two
main groups (experimental and control). Specifically, with
Table 1 Measurements at time points
Baseline 6 months 12 months
SC Demographics
Blood test,
IBD activity,
QoL measure,
Mental health
measures
Blood test,
IBD activity,
QoL measure,
Mental health
measures
Blood test,
IBD activity,
QoL measure,
Mental health
measures
CBT Demographics
Blood test,
IBD activity,
QoL measure,
Mental health
measures
Blood test,
IBD activity,
QoL measure,
Mental health
measures
Blood test,
IBD activity,
QoL measure,
Mental health
measures
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80 patients per arm, the study would have 80% power at the
0.05 level to detect a 20% difference in the proportion of pa-
tients remaining in remission between the +CBT group
(0.80) and SC (0.60) arms. This was based on average data
for remission duration and rates of IBD from several studies
[19-24] and what was thought to be a clinically relevant sig-
nificant difference of 20% as judged by the investigators and
based on data from studies on CBT in irritable bowel syn-
drome, as no reliable estimates from previous studies on
IBD and CBT were available [6]. We intended to recruit
approx. 192 participants to allow for drop-outs of 20%.
Measurements
Disease activity was scored with the Crohn’s Disease
Activity Index (CDAI) [25] for those with CD or the Simple
Clinical Colitis Activity Index (SCCAI) [26] for those with
UC as appropriate. Disease activity was also monitored
using blood tests: CRP, HB, platelet, WCC. The Short Form
36 Health Status Questionnaire (SF-36) was used to
measure Health-Related Quality of Life (HRQOL) [27,28].
It is a comprehensive questionnaire which yields an 8-
scale health profile, and summary measures of HRQOL
(Physical component score, PCS and Mental component
score, MCS).Mental health was assessed using the Hospital
Anxiety and Depression Scale (HADS), the State-Trait
Anxiety Inventory (STAI), the Brief COPE, the Revised So-
cial Readjustment Rating Scale (RSRRS) and the IBD Stages
of Change Coping Questionnaire (IBDSCCQ). The HADS
is a self-assessment mood scale developed for medical out-
patients [29] containing 14 questions graded on a 4-point
Likert scale, with subscales of anxiety and depression, with
a sum score ranging from 0 to 21 for each. The STAI
[30] is used to differentiate between temporary condi-
tion of “state anxiety” and the more general and long-
standing quality of “trait anxiety”. The scale has 40 items,
scored on a 1–4 scale. The Brief COPE [31] is a short 28-
item questionnaire, scored on a 4-point Likert scale and de-
rived from a widely used COPE scale. The questionnaire
identifies a number of adaptive and maladaptive coping
styles. The RSRRS [32] measures 43 stressful events, with
scores interpreted as follows: Low stress <149; Mild
stress = 150–200; Moderate stress = 200–299; Major
stress >300. The IBDSCCQ is a short 10-item questionnaire
designed by these investigators in order to monitor changes
in the process of thinking about coping with IBD. It is as
yet not validated. The questionnaire was derived from the
work by Carr [33] and previous work of the second investi-
gator [34] in the Trans-Theoretical Model of behavioural
change (TTM). The TTM presents individuals as progres-
sing through five stages involving decisions about change
[35]. The stages comprise: Precontemplation, Contempla-
tion, Preparation, Action and Maintenance. High scores on
Precontemplation imply undeveloped coping with IBD and
every subsequent stage corresponds with improved coping,
thus high scores on Maintenance are consistent with excel-
lent coping with IBD.
Outcome measures
IBD remission at 12 months (established using the CDAI
score of <150 or the SCCAI score of >3 and confirmed
by the treating physician) was the primary outcome
measure in this trial; secondary outcome measures were
quality of life as measured on the SF-36 and mental
health status (anxiety and depression as measured on
the HADS and the STAI, coping as measured on the
Brief COPE and the IBDSCCQ, and stress as measured
on the RSRRS) at 6 and 12 months.
Statistical analysis
The study applied the intention-to-treat analyses for the
main group comparisons at 6 months and per protocol
analyses in the CBT dose–response group comparisons.
Participants ‘in need’ were defined as meeting at least one
of the following criteria: being young and thus recently
transitioned from paediatric care (aged 18–20 years); having
high baseline IBD activity despite being considered in IBD
remission by the clinician (CDAI >180; baseline SCCAI
>5); being recently diagnosed (within last 2 years); having
poor coping (a score of 20–25 on either adaptive or mal-
adaptive coping); and high anxiety or depression (HADS
score for either anxiety or depression subscale >/= 15). De-
scriptive statistics including means, SD, counts and propor-
tions were used to describe the study population in the two
treatment arms at baseline, 6 and 12 months. Univariate
group comparisons were conducted with Mann–Whitney
test and the chi-square test. Within group changes over
time were calculated with the Friedman test. The multivari-
ate analyses were conducted using the linear mixed-effects
models which allowed compensating for the missing data.
Two models were constructed: model 1 included time and
group variables and a time-group interaction variable and
adjusted for the outcome variable at baseline; model 2 also
adjusted for sex and age. The p value of less than .05 was
considered statistically significant. Data were analysed using
PASW (SPSS, Inc., Chicago, IL).
Ethical considerations
The study was approved by the Royal Adelaide Hospital
and the University of South Australia Research Ethics
Committees in August 2009. The trial was conducted fol-
lowing the principles of the Declaration of Helsinki
(updated in 2008). Participants gave written informed
consent and the confidentiality was ensured.
Results
Patient recruitment is presented in Figure 1. Overall, 174
patients participated in the study: 90 in the +CBT group
and 84 in SC.
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Baseline demographics, clinical history, medication use,
disease activity, psychological scores, CBT use and
‘in need’ status
Patient demographics and clinical history are presented
in Table 2. CBT participants were more commonly
younger and female. Medication use is presented in
Table 3. Blood results are presented in Table 4.
Disease activity
Although all patients enrolled were considered to be in
IBD remission or to have only mild symptoms by their
treating team, patients’ subjective report seemed to cor-
respond poorly with formal activity scores (Table 5).
Only 13 (7 CBT and 6 SC) participants considered their
IBD control poor, yet at baseline, 18 UC participants had
Invitations sent 
(n = 1811)
Excluded (n = 7)
Not meeting inclusion criteria
(n = 1, IBD became active)
Not contactable
(n = 6)Randomized (n = 176)
Allocated to intervention
(n = 92)
- Withdrew before intervention 
commenced due to time constrains 
(n=2)
-Received allocated intervention (n 
= 67)
-Did not receive allocated 
intervention (n = 23)
(did not access online CBT)
A
ll
o
ca
ti
o
n
E
n
ro
ll
m
en
t
Control group
(n = 84)
F
o
ll
o
w
 u
p
Lost to follow up 6 months 
(n = 39) 
Not contactable n=31
Too busy n=7
Pregnant n=1
Lost to follow up 6 months 
(n = 19) 
(Not contactable n=17
Dementia n=1
Deceased n=1)
A
n
a
ly
si
s
Analyzed at 6 months (n = 
51)
Analyzed at 12 months 
(n=42)
Analyzed at 6 months (n = 
65)
Analyzed at 12 months 
(n=64)
Agreed to participate
(n = 183)
Lost to follow up 12 months 
(n = 48) 
Not contactable n=39
Too busy n=6
Pregnant n=1
Deceased n=1
Cataracts n=1
Lost to follow up 12 months 
(n = 20) 
Not contactable n=18
Deceased n=2
Figure 1 CONSORT diagram showing the flow of participants through the study.
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SCCAI scores >3 and 26 CD participants had CDAI
>150.
Other outcome variables
Both groups reported high levels of stress (>300) (Table 6).
However, they also tended to have low scores on the
IBDSCCQ subscale of Precontemplation and high scores
in Maintenance, which corresponds with already advanced
coping with IBD.
Mode of CBT delivery and its usage
Of 90 CBT participants, 67 (74.4%) used CBT (either face-
to-face or online, at least one CBT activity completed) and
23 (25.6%) did not use it at all. Of CBT users, 44 (48.8%)
used a reasonable amount of CBT program (>4 sessions
face-to-face or at least 20 online logins to activities)
while 23 (25.5%) used a </=4 sessions face-to-face or <20
online activities. Those who used more CBT, had lower
mental QoL at baseline (p = .032), higher depression
scores (p = .019) but were less stressed at baseline than
those who used less (p = .012). Overall, 68 participants
opted to use cCBTand 22 were allocated to F2F CBT. cCBT
users did not differ in age or sex from F2F users (p >.05).
Participants ‘in need’
In the whole sample, there were 74 (42.5%) participants
‘in need’: 34 in the +CBT and 40 in the SC group. Those
‘in need’ in the +CBT and SC groups did not differ sig-
nificantly at baseline on any of the variables of interest.
Primary outcome measure
At 12 months, 30 (73.2%) +CBT and 43 (71.7%) SC partici-
pants remained in remission as measured on disease activ-
ity indices (p = .868). At the multivariate level (adjusting for
baseline), CBT did not significantly change disease activity
at 12 months (CD, p = .669; UC, p = .549). Controlling for
sex and age did not alter the results.
Secondary outcome measures
While at the univariate level +CBT group significantly
improved in mental QoL, depression, trait anxiety, mal-
adaptive coping, Precontemplation and stress, and the SC
group only in stress, between baseline and 12 months
(Table 6), at the multi-variate level, CBT did not signifi-
cantly affect these measures (all p >.05). Further adjusting
for sex and age did not change the results significantly.
Additional analyses
Changes in blood results
At the multi-variate level, CBT did not significantly
affect the CRP, the WCC, the HB or the platelet levels at
6 or 12 months (all p >.05). Further adjusting for sex
and age did not change the results significantly.
Table 2 Demographic characteristics and clinical history by group
+CBT SC
n = 90 n = 84
n (%)
Gender Male 40 (44.4) 54 (64.3)
Speaks language other than English at home Yes 5 (5.6) 6 (7.1)
Marital status Married/de facto 59 (65.6) 50 (59.5)
Employment status Full-time work 38 (42.7) 33 (39.3)
Part-time work 16 (18) 15 (17.9)
Education Year 12 completed 28 (31.1) 21 (25)
Bachelor’s degree 23 (25.6) 17 (20.2)
IBD subtype Crohn’s disease 58 (64.4) 49 (58.3)
Hospital admissions for IBD Yes 52 (60.5) 50 (61)
Operations for IBD Yes 43 (48.9) 31 (37.8)
Suffers from other chronic illness Yes 48 (53.9) 49 (61.3)
Mean (SD)
Age In years 46.5 (15.7) 51.9 (16.9)
Years with IBD symptoms 16.1 (12.1) 14.3 (11.7)
Years since diagnosis 11.8 (10.4) 11.7 (11.8)
Number of IBD specialists 2.6 (1.6) 2.6 (1.9)
How long with current specialist In years 5.7 (6.2) 5.5 (6.1)
How long since your last flare In years 2.6 (3.9) 2.8 (6.6)
How many hospital admissions for IBD Last 5 years 4.7 (3.8) 4.7 (3.6)
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CBT dose–response
No relationship between dose of CBT and all but one out-
come measure was found (p >0.05). When CBT users (at
least one CBT activity completed) were compared to non-
users (in the CBT group but never accessing CBT) in a
multivariate model, the groups were found different on
the IBDSCCQ subscale of Contemplation at 6 months
(p = .020, d = .94). At 12 months the groups were found
different on Contemplation when adjusted for sex and age
(p = .030, d = .66). CBT users had a higher score of con-
templation than non-users, reflecting improvement in
coping with IBD resulting from CBT use.
F2F versus cCBT
While at the univariate level F2F group improved signifi-
cantly in two dimensions of coping (maladaptive coping
and Precontemplation) and cCBT in stress (Table 7), at the
Table 3 Medication use
+CBT SC
n (%)
Baseline 6 months 12 months Baseline 6 months 12 months
n = 90 n = 51 n = 42 n = 84 n = 65 n = 64
Azathioprine 44 (49) 21 (41) 16 (38) 22 (26) 16 (25) 16 (25)
Mesalazine 25 (28) 11 (22) 10 (24) 32 (38) 20 (31) 22 (34)
Sulphasalazine 13 (14) 6 (12) 7 (16) 14 (17) 12 (18) 10 (15)
Corticosteroids 10 (11) 6 (12) 3 (7) 8 (9) 5 (8) 6 (9)
Adalimumab 10 (11) 7 (14) 2 (5) 6 (7) 4 (6) 4 (6)
Infliximab 10 (11) 8 (16) 5 (12) 5 (6) 5 (8) 6 (9)
Vedolizumab 3 (3) 1 (2) 1 (2) 1 (1) 0 0
Methotrexate 4 (4) 4 (8) 2 (5) 4 (5) 2 (3) 2 (3)
Mercaptopurine/thiopurine 2 (2) 2 (4) 5 (12) 4 (5) 0 5 (8)
Vitamins 28 (31) 12 (23) 6 (14) 23 (27) 12 (18) 11 (17)
Fish oil 17 (19) 12 (23) 9 (21) 11 (13) 9 (14) 6 (9)
Probiotics 11 (12) 5 (10) 5 (12) 7 (8) 6 (9) 6 (9)
Paracetamol 24 (27) 14 (27) 10 (24) 18 (21) 10 (15) 11 (17)
Codeine 10 (11) 3 (6) 4 (9) 4 (5) 4 (6) 3 (5)
Ibuprofen 6 (7) 2 (4) 2 (5) 3 (4) 1 (1) 1 (1)
Dextropropoxyphene 4 (4) 1 (2) 0 1 (1) 1 (1) 0
Antispasmodics 2 (2) 1 (2) 1 (2) 1 (1) 2 (3) 4 (6)
Morphine 1 (1) 0 0 2 (2) 0 1 (1)
Oxycodone hydrochloride 1 (1) 3 (6) 2 (2) 2 (2) 3 (5) 0
Tramadol 1 (1) 0 0 1 (1) 0 0
Naproxen 0 1 (2) 0 0 0 0
Medication for depression 24 (28) 14 (29) 10 (24) 20 (27) 12 (18) 12 (19)
Table 4 Blood results by group
+CBT SC
Mean (SD)
Baseline 6 months 12 months Baseline 6 months 12 months
n = 69 n = 57 n = 54 n = 70 n = 62 n = 61
CRP 3.6 (5.4) 5.2 (12.7) 4.9 (10.8) 6.2 (8.3) 10.8 (27.6) 6.5 (10.8)
HB 136.6 (21.8) 136.4 (14.8) 136.6 (13.9) 141.9 (15.4) 142.3 (17.2) 141.3 (17.1)
Platelet 260.9 (72.8) 260.8 (64.7) 267.1 (67.1) 266.4 (63.2) 272.1 (74.8) 263.5 (76.3)
WCC 5.9 (1.8) 8.3 (14.8) 6.1 (1.9) 6.6 (2.1) 6.9 (2.5) 6.9 (2.5)
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multivariate level, no relationship between mode of CBT
delivery and all but one outcome measure was found (p
>0.05). When controlled for sex and age, at 12 months, the
cCBT group had a higher score on the IBDSCCQ subscale
of Precontemplation than the F2F (4.7 (SD = 1.8) vs. 3.3
(SD = 1.9), p = .045, d = .75), which is consistent with less
developed coping with IBD in the cCBT group.
Participants ‘in need’
Those participants ‘in need’ who received CBT had
improved mental QoL at 6 months as compared to SC
(p = .034, d = .56). At 12 months the difference disap-
peared, however, the group ‘in need’ was very small at this
time point (n = 43, +CBT n = 11 and SC n = 32) and the
comparison clearly underpowered (d = .26).
Table 5 Disease activity at baseline and 6 months as measured on the patient subjective measure of disease activity
and disease activity indices
+CBT SC
n (%)
Baseline 6 months 12 months Baseline 6 months 12 months
n = 90 n = 51 n = 42 n = 84 n = 65 n = 64
IBD control Very well 27 (30) 18 (35) 14 (33) 18 (21.4) 17 (26.1) 27 (42)
Reasonably 54 (60) 26 (50) 18 (43) 56 (66.7) 35 (53.8) 30 (47)
Not well 7 (8) 3 (6) 5 (12) 6 (7.1) 7 (10.8) 3 (5)
CDAI Active >150 15 (17) 8 (16) 5 (12) 11 (13.1) 8 (12.3) 8 (12)
SCCAI# Active >3 8 (9) 8 (16) 6 (14) 10 (11.9) 14 (21.5) 9 (14)
Mean (SD)
CDAI 110.8 (72.5) 91.3 (90.3) 84.1 (95.3) 87.4 (104.8) 83.2 (92.2) 88.4 (105.9)
SCCAI 3.4 (1.4) 3.5 (1.8) 2.9 (1.6) 3.2 (1.3) 3.7 (1.6) 3.5 (2.5)
#Contrary to the commonly used cut off point of >2, in this study SCCAI was considered normal between 0 and 3 as only few participants (all considered by
doctors to be in remission) had a score below 3 with subscore of 0 for rectal bleeding.
Table 6 Group differences on mental health variables
+CBT SC
Baseline 6 months 12 months Baseline 6 months 12 months
n = 90 n = 51 n = 42 n = 84 n = 65 n = 64
Mean (SD)
Physical QoL 46.7 (9.3) 46.7 (10.3) 48.3 (10.3) 47 (10.3) 47.2 (9.8) 48.3 (10.1)
Mental QoL 44.8 (11.4) 48.3 (9.2) 45.5 (11.1)1 48.1 (11.5) 48.1 (11.9) 48.3 (11.5)
HADS Anxiety 7.1 (3.9) 5.9 (3.4) 6.5 (4.2) 6.2 (4.3) 5.9 (4.6) 6.1 (4.6)
HADS Depression 4.3 (3.4) 3.5 (2.9) 4.1 (3.3)2 4.4 (4.1) 4.4 (4.1) 4.5 (4.8)
State Anxiety 37.5 (13.1) 34.5 (10.9) 35.9 (13.1) 35.9 (13.7) 35.9 (12.8) 35.3 (13.4)
Trait Anxiety 39.3 (11.9) 36.1 (11.1) 39.5 (12.5)3 37.4 (11.7) 37.5 (11.8) 36.9 (13.1)
Adaptive coping Range: 20–80 (higher is better) 42.7 (12.8) 42.1 (13.6) 40.5 (12.9) 39.5 (11.3) 37.1 (11.2) 37.5 (11.7)
Maladaptive coping Range: 8–32 (lower is better) 10.9 (3.6) 9.8 (2.6) 10.6 (3.7)4 10.7 (3.7) 10.5 (3.3) 10.5 (3.6)
Stress >300 high stress 150–299
moderate stress <150 low stress
638.3 (665.9) 474.2 (653.7) 301.3 (347.5)5 453.6 (490.5) 350.7 (403.4) 338.5 (364.2)6
TTM Stage Pre-contemplation 4.5 (1.6) 4.3 (1.9) 4.2 (1.9)7 4.4 (1.6) 4.2 (1.9) 4.7 (1.9)
Range:2–10 (higher scores
mean greater agreement)
Contemplation 6.7 (2.1) 6.6 (1.9) 6.6 (1.6) 6.3 (2.1) 6.2 (2.1) 6.4 (1.9)
Preparation 6.3 (2.3) 6.5 (2.4) 6.4 (2.3) 5.7 (2.3) 6.1 (2.2) 6.1 (2.1)
Action 5.8 (2.2) 6.3 (2.3) 6.1 (2.3) 5.5 (2.1) 5.8 (2.3) 5.9 (2.3)
Maintenance 7.1 (1.9) 7.7 (1.7) 7.3 (1.8) 7.2 (1.3) 7.1 (1.9) 7.3 (1.9)
1A significant improvement in mental QoL over 12 months in the +CBT group (chi2 (2) = 8.63, p = .013).
2A significant improvement in HADS Depression over 12 months in the +CBT group (chi2 (2) = 8.02, p = .018).
3A significant improvement in Trait Anxiety over 12 months in the +CBT group (chi2 (2) = 6.32, p = .042).
4A significant improvement in maladaptive coping over 12 months in the +CBT group (chi2 (2) = 12.12, p = .002).
5A significant drop (improvement) in Precontemplation over 12 months in the +CBT group (chi2 (2) = 6.29, p = .043).
6A significant improvement in stress over 12 months in the +CBT group (chi2 (2) = 11.04, p = .004).
7A significant improvement in stress over 12 months in the SC group (chi2 (2) = 8.71, p = .013).
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Attrition
At 6 months, 39 (43%) CBT group participants and 19 (23%)
SC were lost to follow up (p <.001) indicating a higher drop-
out rate in the CBT group. The overall attrition at 6 months
was 33%. Attrition at 6 months was similar in the cCBT ver-
sus F2F group (33 (48%) vs. 6 (27%), p = .080). At 12
months, 48 (53%) CBT group participants and 20 (24%) SC
were lost to follow up (p <.001). The overall attrition at 12
months was 39%. Attrition at 12 months was higher in the
cCBT versus F2F group (41 (60%) vs. 7 (32%), p = .020).
Discussion
This trial is the largest to date to explore the potential
usefulness of CBT in managing disease activity and men-
tal health in IBD. A pragmatic approach to its delivery
was chosen, offering participants a choice between face-
to-face and online CBT, designed to mirror each other.
The most important finding of the study is that adding
CBT to standard care was not found protective of IBD
remission over a period of 12 months. Further to this
observation, participants who received CBT were not
found to differ in their scores on anxiety, depression
and coping measures at 6 months when controlling for
baseline, a finding in contrast to previous small studies
[36-40] and unusual given the high efficacy of CBT in
treating anxiety and depression [41]. It can perhaps be
explained by low anxiety and depression scores at base-
line, and thus since the mental health of these partici-
pants was generally good at the outset, there was little
that could be gained from the intervention. A subgroup
analysis of participants ‘in need’ (with high scores on
mental health subscales), showed that CBT was effective
in improving this group’s QoL at 6 months, thus confirm-
ing that CBT works in those who need it. At 12 months,
due to attrition, the comparison was underpowered and
thus future studies should establish long-term effect of
CBT on QoL in the subgroups of IBD classified as ‘in need’.
A study using psychodynamic therapy for a similar unse-
lected sample also showed no relationship between psycho-
therapy and disease activity in IBD, although unlike in our
study, theirs showed trends towards improved disease ac-
tivity and fewer surgical interventions [42]. On the other
hand Keefer et al. [43] showed that gut-directed hypno-
therapy prolongs clinical remission in IBD. Though Keefer
et al.’s study [43] had a small sample size, their promising
results may indicate that hypnotherapy rather than therap-
ies such as CBT or psychodynamic may play a role in
maintenance of IBD remission.
Table 7 Outcome variables by mode of CBT delivery
F2F cCBT
Baseline 6 months 12 months Baseline 6 months 12 months
n = 22 n = 16 n = 15 n = 68 n = 35 n = 27
Mean (SD)
Physical QoL 43.2 (11.1) 41.1 (13.4) 43.5 (12.1) 47.7 (8.4) 49.2 (7.7) 50.9 (8.4)
Mental QoL 42.3 (10.8) 48.1 (7.7) 43.8 (10.7) 45.5 (11.5) 48.4 (9.9) 46.4 (11.4)
HADS Anxiety 7.8 (3.1) 6.2 (2.0) 6.7 (2.7) 6.7 (4.2) 5.8 (3.8) 6.4 (4.8)
HADS Depression 5.1 (2.7) 4 (2.5) 4.7 (2.9) 4.1 (3.6) 3.3. (3.1) 3.7 (3.5)
State Anxiety 41.1 (12.9) 36.1 (10.8) 38.3 (10.1) 36.4 (13.1) 33.8 (11.1) 34.6 (14.5)
Trait Anxiety 43.3 (11.2) 36.3 (13.7) 42.2 (10.2) 38.1 (11.9) 36 (9.7) 37.9 (13.5)
Adaptive coping Range: 20–80 (higher is better) 44.1 (10.3) 45 (13.6) 46.1 (12.5) 42.2 (13.5) 40.6 (13.6) 37.6 (12.4)
Maladaptive coping Range: 8–32 (lower is better) 11.8 (2.7) 10.3 (1.9) 11.4 (3.4)1 10.6 (3.8) 9.5 (2.9) 10.2 (3.8)
Stress >300 high stress 150–299
moderate stress <150 low stress
660.4 (606.1) 755.8 (934.2) 406.1 (471.6) 630.7 (689.6) 345.5 (434.7) 240.9 (241.5)2
TTM Stage Pre-contemplation 4.6 (1.3) 3.5 (1.4) 3.3 (1.9)3 4.5 (1.7) 4.6 (2.1) 4.7 (1.8)
Range:2–10 (higher scores
mean greater agreement)
Contemplation 7.1 (1.9) 7 (1.7) 6.8 (1.9) 6.5 (2.1) 6.5 (1.9) 6.5 (1.4)
Preparation 7.2 (1.9) 7.4 (2.1) 7.3 (2.1) 6 (2.3) 6.2 (2.5) 5.9 (2.4)
Action 6.8 (2.1) 7.3 (2.1) 7.1 (2.1) 5.4 (2.1) 5.8 (2.3) 5.5 (2.3)
Maintenance 7.6 (1.6) 8 (1.2) 7.5 (1.7) 6.9 (2.1) 7.6 (1.8) 7.2 (1.9)
CDAI 140.3 (87.1) 75.3 (83.3) 79.5 (111.6) 101.2 (65.5) 97.3 (93.7) 86.9 (88.2)
SCCAI 3.7 (1.1) 4.3 (1.4) 4.0 (1.1) 3.2 (1.5) 3 (1.9) 2.3 (1.5)
1A significant improvement in maladaptive coping between baseline and 12 months in the F2F group (chi2 (2) = 7.20, p = .027).
2A significant improvement in stress between baseline and 12 months in the cCBT group (chi2 (2) = 8.79, p = .012).
3A significant drop (improvement) in Precontemplation between baseline and 12 months in the F2F group (chi2 (2) = 12.3, p = .002).
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Regarding the participants ‘in need’, this group was
identified based on the recommendations from previous
papers [8,44]. Indeed, looking at this subgroup separ-
ately, we showed that CBT does improve mental QoL at
least at short-term. Curiously, no improvements in anx-
iety or depression were observed in the group ‘in need’,
however, given its size (34 CBT and 40 controls), it is
possible that if the sample had been larger these im-
provements would have appeared and possibly a longer
observation period could also verify this finding. Future
studies should focus on targeting psychotherapeutic in-
terventions at the group ‘in need’ rather than the general
IBD population and should confirm these results on a
larger sample to allow for significant attrition.
Interestingly, this trial did not show F2F to be signifi-
cantly different to cCBT in efficacy, with the exception
of one dimension of coping (showing F2F group to
fare better at 12 months), although, admittedly the trial
was not powered for this subgroup analysis. Participants
nearly always preferred the online CBT delivery as it fit-
ted with their life style and commitments and thus it is
reassuring that the efficacy of the modalities was similar.
This mode of delivery also allowed for recruiting partici-
pants who usually do not take part in trials as they live
in remote areas, increasing the generalisibility of our
data. However, the attrition in the online CBT group was
significantly larger than in the F2F group and the ways
to address high attrition should be examined in future
studies. Alternatively larger samples could be utilised.
Further, and interestingly, we observed no marked
relationship between the amount of CBT used and the
outcomes. Only when we compared users to non-users
(in the CBT group but not using the program) we
showed some difference in the IBDSCCQ subscale of
Contemplation at 6 and 12 months, demonstrating that
those who used CBT improved their coping with IBD.
However, we failed at demonstrating that a particular
dose of CBT is effective as all the comparisons between
users and controls were not statistically significant.
Finally, while this trial is the largest to date, it unavoid-
ably has limitations. Its design does not comply with the
classic RCT requirements in which participants are aware
they may be offered an intervention or the placebo. Given
impossibility of blinding the intervention, we decided to
withdraw the information regarding the intervention from
the controls. Thus, the controls had been informed they
participated in an observational study on mental health in
IBD. Further, having extensive clinical experience with this
population who is in the productive age, often in full-time
employment but also frequently caring for young families,
we gave participants the option of choosing the mode of
CBT delivery. If the study was to be conducted using the
classical RCT design, we should have randomly allocated
participants to each mode of delivery. In addition, while we
conducted the analysis of CBT usage, there is no certainty
that our statistics on the online CBT usage are 100% re-
flective of the actual use. A significant number of patients,
particularly, the older ones, preferred to print the materials
and work on them offline and thus the short time spent on
a given activity may not be a reflection of it not being
read or acted on. Perhaps because of it we did not show
a significant relationship between CBT usage and the
outcomes. Disease activity throughout the trial was
measured using disease activity indices and monitoring
blood. Future studies could use calprotectin and/or en-
doscopy to monitor disease activity, although the latter
would likely lead to low participation and drop-out due
to participant burden. Using calprotectin was not pos-
sible in this trial as calprotectin had not been available
at the participating hospitals when we commenced the
study and the study only received a limited funding.
Further, the sample size calculation was prepared for
the main group comparisons only and the study was
not powered for the subgroup analyses. However, no
good estimates for what to base the subanalysis predic-
tions on had been available and the future trials can
use the present study data to provide adequate power
calculations. Finally, although the attrition in this trial
was approximately 30% at 6 months and nearly 40% at
12 months, significantly more CBT users than control
group participants withdrew from the study, possibly
reflecting the study burden. However, high attrition is a
known phenomenon in the self-directed psychotherapy
studies for those in the intervention group [18,45], and
thus our study does not differ in respect to this from
other research in the field.
Conclusions
CBT does not seem to improve disease activity at 12
months since baseline in the unselected patients with
IBD although it offers promise to patients ‘in need’. Fu-
ture studies should direct psychological interventions to
patients ‘in need’ and attempt to recruit larger samples
to compensate for significant attrition when using online
CBT. Longer follow-up is needed to clarify any potential
longitudinal effect of CBT in IBD management.
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